According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

https://www.tipranks.com/news/the-fly/gsk-shares-shorted-by-leading-u-s-hedge-fund-the-times-reports GSK (GSK) announced that the European Medicines Agency, EMA, has ...

GSK plc announced that new drug applications have been accepted for review by the China National Medical Products Administration (NMPA) and submitted to the Japanese Ministry of Health, Labour and ...

The company anticipates five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. This robust pipeline supports GSK’s long-term growth ...